

21 March 2024  
EMA/MB/585245/2023 Noted  
Management Board meeting of 21 March 2024

## Outcome of written procedures finalised during the period from 07 December 2023 to 11 March 2024

### Issues for consideration

This document is presented in accordance with Article 4 (5) of the Management Board rules of procedure regarding the outcome of the written procedures.

During the period from 07 December to 11 March 2024, the Board was consulted 7 times via written procedure, of which 3 consultations concerned membership in the CHMP and CVMP, and 4 additional consultations, as listed below:

- Consultation no. 13/2023 on the appointment of Els Dewaele as CVMP member as proposed by Belgium ended on 03 January 2024. The mandate of the nominee commenced on 04 January 2024.
- Consultation no. 01/2024 on the appointment of Kristina Lehmann as CVMP alternate as proposed by Finland ended on 31 January 2024. The mandate of the nominee commenced on 01 February 2024.
- Consultation no. 02/2024 on the appointment of Alia Michaelidou-Patsia as CVMP alternate as proposed by Cyprus ended on 07 March 2024. The mandate of the nominee commenced on 08 March 2024.
- Consultation procedure for the adoption of revised Rules of Procedure of Committee for Medicinal Products for Human Use (CHMP) ended on 9 February at 17:00hrs (CET). The procedure was adopted.
- Consultation procedure for the adoption of Amending Budget 01-2023 ended on 21 December 2023 at 17:30hrs. The procedure was adopted.
- Consultation procedure for the adoption of Amending Budget 01-2024 ended on 5 January 2024 at 12:00hrs. The procedure was adopted.
- Consultation procedure for the adoption of non-automatic carry forward of appropriations from 2023 to 2024 ended on 26 January 2024 at 17:30hrs (CET). The procedure was adopted.

In accordance with the Board's decision of 18 March 2010 relating to the '*Procedure for the consultation of the Management Board on new appointments of CHMP and CVMP members and alternates*' (EMA/MB/353835/Rev.2), the Board shall be provided with a periodic overview of renewed



memberships in the CHMP and CVMP. Renewed memberships also include those memberships where the member has been re-nominated as an alternate or *vice versa*:

Country	Name	Membership <sup>1</sup>	Committee
Czechia	Blanka Hirschleova	Co-opted member <sup>2</sup>	CHMP
Finland	Minna Leppänen	Member	CVMP
Germany	Jan Mueller-Berghaus	Member	CHMP
Malta	John-Joseph Borg	Member	CHMP
Portugal	Bruno Sepodes	Member	CHMP
Portugal	Carla Torre	Co-opted member <sup>2</sup>	CHMP
Spain	Sol Ruíz	Co-opted member <sup>2</sup>	CHMP

Action requested of the Board

NOTE the presented cover note:	EMA/MB/585245/2023

Additional background

The document is intended for publication on the Agency’s external website.

<sup>1</sup> Membership referred in this column is the membership that was indicated in the nominating correspondence.  
<sup>2</sup> Co-opted members are appointed by the CHMP based on required areas of scientific expertise, following a call for nominations